References
- Blevins AM, Lashinsky JN, McCammon C, Kollef M, Micek S, Juang P. Incidence of acute kidney injury in critically ill patients receiving vancomycin with concomitant piperacillin-tazobactam, cefepime, or meropenem. Antimicrob Agents Chemother. 2019;63(5):e02658. https://doi.org/10.1128/aac.02658-18.
- Navalkele B, Pogue JM, Karino S, Nishan B, Salim M, Solanki S, et al. Risk of acute kidney injury in patients on concomitant vancomycin and piperacillin-tazobactam compared to those on vancomycin and cefepime. Clin Infect Dis. 2017;64(2):116–23. https://doi.org/10.1093/cid/ciw709.
- Rutter WC, Cox JN, Martin CA, Burgess DR, Burgess DS. Nephrotoxicity during vancomycin therapy in combination with piperacillin-tazobactam or cefepime. Antimicrob Agents Chemother. 2017;61(2):e02089. https://doi.org/10.1128/aac.02089-16.
- Maxwell RR, Egan-Sherry D, Gill JB, Roth ME. Management of chemotherapy-induced febrile neutropenia in pediatric oncology patients: a North American survey of pediatric hematology/oncology and pediatric infectious disease physicians. Pediatr Blood Cancer. 2017;64(12):e26700. https://doi.org/10.1002/pbc.26700.
- Haeseker MB, Croes S, Neef C, Bruggeman CA, Stolk LML, Verbon A. Vancomycin dosing in neutropenic patients. PLoS One. 2014;9(11):e112008. https://doi.org/10.1371/journal.pone.0112008.
- Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179–84..
- Filippone EJ, Kraft WK, Farber JL. The nephrotoxicity of vancomycin. Clin Pharmacol Ther. 2017;102(3):459–69..
- Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, Dalovisio JR, Levine DP. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases society of America, the American society of health-system pharmacists, and the society of infectious diseases pharmacists. Clin Infect Dis. 2009;49(3):325–7.